Bould Opportunities Share Discussion Threads

[nickg2] 13/5/2021 15:40

Cizzle Biotechnology is a spin-out from the University of York,founded in 2006 around the work of Professor Coverley and colleagues, and is focused on patent protected technology for the early detection of lung cancer through the development of a blood test for the CIZ1B biomarker

[nickg2] 13/5/2021 15:32

13 May 2021
Bould Opportunities Plc
(“Bould Opportunities” or the “Company”;)

Results of Annual General Meeting and General Meeting

Bould Opportunities is pleased to announce that at both its Annual General Meeting and General Meeting held earlier today (“AGM” and “GM” respectively) all resolutions proposed to the meetings (the “Resolutions”) were duly passed on a poll.

Following the passing of the Resolutions the Company can confirm, inter alia, that the acquisition of Cizzle Biotechnology Technology Limited and proposed Placing has been completed, the Share Reorganisation is effective, application will be made for the Company’s name to be changed to Cizzle Biotechnology Holdings Plc and the Company’s Enlarged Share Capital will be admitted to the Standard Listing segment of the Official List and trading on the Main Market of the London Stock Exchange.

Trading in the Company’s shares is expected to begin at 8.00 a.m. on 14 May 2021 under the ticker CIZ.

[nickg2] 13/5/2021 13:23

AGM Today!

[nickg2] 27/4/2021 11:56

A University of York spinout is set to become listed on the London Stock Exchange following its acquisition in a £21m deal.

Bould Opportunities has acquired Cizzle Biotechnology and raised more than £2.2m, conditional on shareholder approval.

The combined entity will be listed on the Standard list and London Stock Exchange, with the support of law firm Shakespeare Martineau.

Cizzle Biotechnology is a spin-out from the University of York focused on patent protected technology for the early detection of lung cancer through the development of a blood test for the CIZ1B biomarker. It has been sold to Bould Opportunities in London for a total consideration of £21m.

Bould Opportunities, formerly an AIM-quoted company, was seeking acquisitions after disposing of its existing trading subsidiaries.

Allan Syms, chairman of Bould Opportunities, said: "I am delighted to have exchanged on the acquisition of Cizzle Biotechnology. I believe that the acquisition presents huge value for Bould Opportunities, with a technology looking to address an urgent clinical need.

"Shakespeare Martineau has been excellent in supporting us and Cizzle Biotechnology through the process, they understand our sector and have helped us get the best possible outcome for all stakeholders.

"Lung cancer is incredibly hard to diagnose at an early stage as there are few clinical symptoms. However, I believe that Cizzle Biotechnology can provide a solution to this problem through the blood test it is developing for the early detection of a majority of the different forms of lung cancer."

Keith Spedding, partner and business transaction specialist at Shakespeare Martineau, led the deal on behalf of Cizzle Biotechnology Ltd and added: "The biotech industry is absolutely fascinating, we are seeing huge movements and rapid growth in this market as clinical need increases and technology and innovation races to keep up.

"It's been a long journey but great to get this deal done which will allow Cizzle now to continue to develop its blood test for the benefit of many in the continuing fight against cancer."

Spedding was assisted by Jennie Davis and Gweni Rees-Evans.

Allenby Capital Limited acted as financial adviser and Novum Securities as broker.

Dominic Prentis and Richard Pull of Goodman Derrick acted for Bould.

hxxps://www.insidermedia.com/news/yorkshire/university-of-york-spinout-acquired-in-21m-deal

[nickg2] 27/4/2021 11:55

Bould Opportunities PLC - cash shell - Agrees to buy Cizzle Biotechnology Ltd for GBP21 million, and intends for shares to be admitted to the Standard Listing segment of the Official List and trading on the Main Market of the London Stock Exchange, all of which are subject to shareholder approval at a general meeting.

Bould, formerly known as Photdisabled LED Group, was classified as a cash shell on April 5. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006, and is focused on patent protected technology for the early detection of lung cancer through the development of a blood test for the CIZ1B biomarker.

Bould also raises GBP2.2 million to provide working capital for the enlarged company's strategy.

Chair Allan Syms says: "I am delighted that we are today announcing the proposed acquisition of Cizzle Biotechnology. Cizzle Biotechnology has developed a simple blood test for the early detection of lung cancer based on detecting a circulating protein biomarker, CIZ1B, in the blood stream.

"I believe that the acquisition of Cizzle Biotechnology presents a compelling potential value opportunity for the company, with a technology looking to address an urgent clinical need. I would like to thank both the Bould and Cizzle shareholders for their considerable patience and hope that Bould shareholders support the proposals at the forthcoming general meeting."

The GM will be held on May 13.

By Paul McGowan; [e-mail]

hxxps://www.morningstar.co.uk/uk/news/AN_1619191000245668400/in-brief-bould-opportunities-sets-sights-on-cizzle-biotechnology.aspx

[pilkersa] 03/3/2021 11:38

Very quiet here. Anyone thinks we will still relist?

[nicholasc] 11/8/2020 13:59

Are we rich yet?

[texaschaser] 01/5/2020 16:11

To boldly go where lots of shares like these have gone before. Down pan.

[nicholasc] 26/4/2020 08:29

Target identified. Let's see how this develops.From RNS:To that end the Company, together with its various professional advisers, has been working  for some time to complete the acquisition of an identified target (the "Target") in the biotechnology sector (the "Proposed Transaction"). The Proposed Transaction , if completed, would comprise the acquisition of a company with a technology and patent portfolio focussed on the early detection of a specific cancer. This is an exciting opportunity to provide a new diagnostic test for cancer that addresses unmet clinical need for early detection.  Early detection is proven to increase five year survival rates.

[salierizen] 10/4/2020 21:31

Hahahahah delisted, Not surprised at all. Well done Bod. Amazing job lol lifestyle co.

[pilkersa] 08/4/2020 07:37

All progressing well if somewhat slowly.....

[godolphin] 06/4/2020 09:43

Suspended on the 7th so due to be cancelled on the 8th, Wednesday.

[nicholasc] 04/4/2020 12:25

Hoping for an update here next week.Good luck to all involved.

[salierizen] 16/3/2020 19:58

Crooks crooks crooks crooks crooks crooks crooks crooks. I told you lol lol never trust a man in a suit. R.I.P BOU Aye

[jimmymcgill] 22/1/2020 22:06

silence me I dare you

[madchatter2] 22/1/2020 19:40

Jimmy can you just post what you found out please.

[jimmymcgill] 16/1/2020 20:04

better call...."Its all good man."

[counting cards] 15/1/2020 12:03

watch what you say mate.

[jimmymcgill] 14/1/2020 15:23

silence me I dare you